Friday, 16 October 2026European Markets

CHAUSSERIA Stock Bullish Momentum With A 33% Rise In The Last 21 Sessions

Loading stream...

(vianews) - shares of chausseria (cac 40: chsr.pa) rose by a staggering 33% in 21 sessions from €5 to €6.65 at 14:56 est on monday, following the last session's downward trend. cac 40 is dropping 1.3% to €7,278.86, after five sequential sessions in a row of gains.

chausseria's last close was €6.65, 16.88% below its 52-week high of €8.00.

about chausseria

chausseria designs, manufactures, and markets women's shoes. the company markets its products under the chausseria and janie philip brands. chausseria is headquartered in paris, france.

earnings per share

as for profitability, chausseria has a trailing twelve months eps of €0.47.

pe ratio

chausseria has a trailing twelve months price to earnings ratio of 14.15. meaning, the purchaser of the share is investing €14.15 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.29%.

volume

today's last reported volume for chausseria is 135 which is 419.23% above its average volume of 26.

volatility

chausseria's last week, last month's, and last quarter's current intraday variation average was 12.58%, 7.03%, and 22.42%.

chausseria's highest amplitude of average volatility was 32.88% (last week), 22.42% (last month), and 22.42% (last quarter).

yearly top and bottom value

chausseria's stock is valued at €6.65 at 14:56 est, way below its 52-week high of €8.00 and way higher than its 52-week low of €5.00.

more news about chausseria (chsr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com